- Ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy
This study is looking for better ways to treat advanced lung cancer that has not responded to previous treatments. It checks how well new medicines work with or without standard therapy, hoping to shrink tumours.
For: Non-small Cell Lung CancerHungary · Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
This study is looking at new ways to treat advanced small cell lung cancer for the first time. It combines Pembrolizumab with other medications to see how well they work together and if they are safe.
For: First-line treatment of participants with extensive-stage small cell lung cancerPoland · Hungary · Spain - Active not recruitingPHASE2
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
This study looks at new drug combinations for advanced bowel cancer that has specific genetic markers (MSI-H or dMMR). It compares these combinations with existing treatments to see if they are more effective and safe for patients.
For: Colorectal CancerUnited States · Belgium · Canada - Active not recruitingPHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
This study looks at new drug combinations for advanced kidney cancer that has not responded to previous treatments. It aims to see how safe and effective these new combinations are.
For: Carcinoma, Renal CellUnited States · Australia · Canada - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
This study is looking at new ways to treat advanced ovarian, fallopian tube, or primary peritoneal cancer before surgery. It's testing if adding new drugs to standard chemotherapy can shrink tumours more, using a simple blood test to check progress.
For: Primary peritoneal cancer/Fallopian tube cancerItaly · Spain · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
This study is testing different new drug combinations with pembrolizumab and chemotherapy for people with advanced non-small cell lung cancer who haven't had treatment yet. It's looking at how well the new combinations shrink tumors and if they have side effects.
For: non-small cell lung cancerItaly · Hungary · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It combines Pembrolizumab (Keytruda) with other new medicines like rolistobart or MK-4830 to see how well they shrink tumours and help people live longer, while checking for side effects.
For: Non-small Cell Lung Cancer (NSCLC)Hungary · Italy · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C
This study is for people in the UK with advanced melanoma, a type of skin cancer. It's testing new ways to treat it, sometimes combined with an existing medicine called Pembrolizumab (Keytruda). The main goals are to see how safe the new treatments are and how well they work.
For: Stage IIIB or IIIC or IIID melanomaFrance · Italy